Advertisement
Advertisement
U.S. Markets open in 8 hrs 53 mins
Advertisement
Advertisement
Advertisement
Advertisement

Relief Therapeutics Holding AG (RLFTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0702+0.0024 (+3.61%)
At close: 03:59PM EST
Advertisement
Sign in to post a message.
  • S
    Sam
    Bullish
  • L
    Lars
    Anticipated pharmacological role of Aviptadil on COVID-19

    https://link.springer.com/article/10.1007/s11356-021-17824-5
    Bullish
  • E
    Equalizer
    Wow. 13-10 vote.
    To recommend use of a drug to reduce The absolute reduction in risk of severe disease or death was 3%.
    3%.
    That helps 3%, so good for them.
    That’s terrific.
    Every bit helps.
    Side effects on the other 97%?
    I’m not sure.
    And meanwhile Aviptadil helps by 2.5x (250%) to 4x (400%).
    Who is in charge of these decisions?
    Bullish
  • Z
    Zye of Relief
    I posted some time back about my VA Dr listening patiently while I described VIP /Aviptadil/RLF100, RT and NRxP CA and partnership to bring this drug to trial, approval and manufacture. For those who remember we ran into each other at the grocery and he informed me he had made a purchase. Today at my appointment we touched on the subject, at my urging, of this being a painful time. All he did was smile and say relax, were gonna be just fine, outlining his many reasons. Some of those reasons are in the wording of FDA docs and denials. He also shared the fact he has over 2 m share at an .11 avg. I trust my doc for a whole host of reasons and he added more reasons today. Everyone relax and enjoy your weekend. Hug your families, smell the flowers, enjoy the colors of your world today and tomorrow. And Wong, go find my wife in Manhattan, shes somewhere near Lincoln Centrea nd have a drink with her... we all have to start meeting each other at some point! LONGER AND STRONGER EVERYDAY-1 😇
    Bullish
  • Z
    Zorro
    Regarding the Type A meeting, the PR was dated 11/4/21 and stated a Type A meeting was requested the previous week (ending Oct 29th).

    From the "SOPP 8101.1: Regulatory Meetings with Sponsors and Applicants for Drugs
    and Biological Products" https://www.fda.gov/media/84040/download

    The following highlights:

    Type A Meeting - A meeting which is necessary for an otherwise stalled drug development program to proceed (a “critical path” meeting) or to address an important safety issue.

    Meeting requests will be evaluated promptly and meetings will be scheduled and completed within the goal dates for the appropriate product type.

    In some cases, while the requester may request a Face-to-Face, or teleconference meeting, CBER may determine that a written response to the requester’s questions would be the most appropriate means for responding to the meeting request.

    If the requested date for any meeting type is greater than the specified timeframe in the most recent goals letter, the meeting date should be within 14 calendar days of the requested date.

    1. Meeting packages are prepared by the requester and submitted to CBER according to the schedule in the appropriate appendix of this SOPP based on the product type (i.e., BsUFA, GDUFA, or PDUFA). See the appropriate appendix for additional information on the content of meeting packages.

    2. The meeting package provides summary information relevant to the product and supplementary information needed to develop responses to issues raised by the requester.

    3. It’s critical that the entire meeting package content support the intended meeting objectives and be organized according to the proposed agenda.

    CBER meeting minutes are the official record of the meeting and should be issued no later than 30 calendar days following the meeting.

    I tried to look up companies that have recently announced when Type A meetings were scheduled and only found for Medexus: "The Type A Meeting has been scheduled to occur on November 23, 2021."
    https://www.medexus.com/en_US/investors/news-events/press-releases/detail/98/medexus-pharmaceuticals-announces-type-a-meeting-with-fda

    Have not seen an announcement by Nrx about a meeting scheduled yet. We may not hear about it until it is over(?) Per the SOPP it should have been scheduled within 14 days of the requesters date(?) This assume they have submitted a package timely.

    Minutes to released within 30 days after by FDA. If FDA likes results of the meeting they move to issue FDA and announce such?
  • M
    Max
    Let's break on friends of money. It is our chance and it can at least materially change the lives of each of us. A matter of time before more medicines will be used. Ours will emerge victorious. We are so close. And I am fully convinced that we will win.
    Bullish
  • G
    Glenn
    0.52 is more than 3-times my average, I would be very happy with that stockprice 6 months from now!
    Bullish
  • P
    Pebbles
    California Omicron patient was fully vaccinated but it didn't prevent infection... A COVID vaccine resistant strain will be reality within 12 months as COVID continues to mutate inside vaccinated people... How many shots do they expect people to take? 50? 100? 500?
    Bullish
  • S
    Serge
    SIX finish 0.0676 +5.62%
  • D
    DD to win
    So some new appointments for upper management released today. One seems to be a buy out specialist. Just food for thought.

    "Before that, Dr. Varawalla was Managing Director of Clinstrat Ltd, a life science and healthcare business consultancy, where, among other projects, she worked with private equity firms to develop the investment thesis and business plan for the buy-out of BTG plc's specialty pharmaceutical business unit, valued at approximately $1 billion. Before that, Dr. Varawalla was Senior Vice President and Head of Clinical Development at BTG International plc, where she led a global team responsible for clinical development of the company's product portfolio across both pharmaceutical and medical device business units before it was acquired by Boston Scientific for $4.4 billion in 2019."
  • D
    DasKloster 1000
    According to his LinkedIn profile, Della Corte was responsible for the clinical development of Aviptadil in Covid-19 in the EU.
    Perhaps the arrival of Nermeen Varawalla will finally unlock Relief's efforts on that front.
    We really need to find common ground with Javitt for the sake of patients in Europe.
    I imagine that Javitt did not like Della Corte very much. The change comes at the right time.
  • S
    Serge
    RT 0.0688 +7.5% NO WALL UP
  • S
    Serge
    RT 66
  • m
    matthewk
    When a contract is agreed upon by two parties, it is generally presumed that each will deal with the other honestly, fairly, and in good faith. However, some parties enter into agreements with no intention of ever living up to their terms, or they knowingly misrepresent the quality of something that is being bought or sold. These intentions to mislead or deceive in order to gain an advantage are characteristics of bad faith. Can we please maintain a little faith. Mediation is supposed to happen early January. It can't come quick enough. I hope for everyone invested in this, that's as far as it goes. Any further then mediation, and it will not end well for either party. Good luck to everyone.
  • S
    Serge
    SIX its Green because good company
    RT 0.0644 11h10
  • M
    Max
    The whole development of this company promises good things. The concept is right and fits. I am also optimistic about these company acquisitions with the expansion of the pipeline. I only accuse RLF's leadership of not taking faster and more aggressive action against this theft of their product. Imagine if RLF had worked with a really serious larger pharmaceutical company. Well, this new Covid variant significantly increases the chances again, as we are again at the beginning of a disaster. Nevertheless, I now see this stock as no longer risky. I am confident.
    Bullish
  • B
    BBB
    Did everybody noticed The significance in this new article ,NRX actually referred to Relief therapeutics Aviptadil throughout the entire news release, NRX has stopped cutting Relief therapeutics Aviptadil out of the news articles, it reads Aviptadil /zyesami almost entirely throughout the article ,and during the doctor's Schoenfeld Part, he only referred to Aviptadil in his study Analysis And never used the term zyesami in his section of the news article , Sometimes you have to read between the lines to see things are working out between the 2 companies and That data analysis is being directed towards Aviptadil /RLFTF PROUD
  • C
    Commsman
    nickles on the NRXP board just found a brand new inhaler trial registered on clinical trials dot gov which was just initiated today.
  • S
    Serge
    I think some people are knowledgeable about SIX
    RT 0.0692 8.12%
  • M
    Max
    My cost price at 0.28. but I see absolutely no problem with it. It may take a little longer but I keep stocks longer anyway.
    Bullish
Advertisement
Advertisement